A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses
about
Nonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenDeletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-CImproving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensRecombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysVirological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.A mechanism for the inhibition of DNA-PK-mediated DNA sensing by a virus.Enhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-κB inhibitor.Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve ImmunogenicityModified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in miceVaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.Enhancing poxvirus vectors vaccine immunogenicity.Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infectionVaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulenceAttenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Clinical applications of attenuated MVA poxvirus strain.Vaccinia virus inhibits NF-κB-dependent gene expression downstream of p65 translocation.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciDeletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy.Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization.Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.The Gene of Goatpox Virus Encodes an Inhibitor of NF-κB and Apoptosis and May Serve as an Improved Insertion Site To Generate Vectored Live Vaccine
P2860
Q26861148-E9D5D0F6-FFEC-4474-B2F8-58527B4E5C4AQ26995078-0CC23628-881A-4E45-9D3D-7FE362959086Q26995905-034AC180-EA97-4FE0-BE03-F40DF0D3C7D2Q27302081-B97FE139-AEB9-43B9-A089-FCCA0D22CFD6Q27306437-045412BA-FD1C-499C-8CAF-D64E8949FEDFQ34182371-BA4ADDBF-9B91-424D-A26C-950F7854B322Q34247289-6B05E90E-EF17-4D4F-A22E-B88C97E26EA9Q34465228-B018ED0A-1D6B-4963-8F49-8FC60B003367Q34594898-2B3B426D-F77B-4896-BDAD-F8B335FCD37FQ34796206-4BA275B3-E3E9-4720-BA4D-29E22BA40DD9Q34991112-CB446007-72D1-449D-8B74-4DCEA614D440Q35008790-36C19A4E-9D8E-45C3-8AF6-1983A0285274Q35512353-C4F4D25B-5350-4D58-9ED2-1BECA607978DQ35656345-2A128740-8E46-4553-BDCE-E062CEDE8366Q35943471-CA4DF2B8-7847-469E-A877-2548A1148B1AQ35943846-38E78B9B-6838-4D20-BFD6-F5102562647DQ36210308-B254FD9B-D918-4721-BA59-BDD9942C6545Q36911682-B4BA0789-B4AD-47D3-8080-CE56AA89BCF1Q36978452-F20F00B7-05B7-4C5C-B1F5-123CD42D8D70Q37006800-975520E2-CA88-4159-A27E-9E30A93DF26AQ37109669-E5A4EAC8-D4F1-4F23-8124-49D89A5F3463Q37209483-106CDE1A-7EED-4C74-9675-148E072773BBQ37255121-E8B81AC7-0030-4F02-93F5-7976E0F5A954Q37308720-204F07FC-19C2-452D-8654-5CD9887EAE78Q37547241-F5ACD2DB-FAE7-4909-AF36-1FCE489E238DQ37643731-80849066-944D-43E6-9D7F-EB1199532E38Q37643733-5F589949-20D3-4804-B1F4-F833D5E35E85Q38096490-BDA72C80-2405-4CEE-8083-3EB7EFABC6D2Q38156198-4ABABF13-83B4-4239-9815-26213E1C3BB6Q38326055-B8520355-2AB6-48A6-8862-4C0974D911D6Q40071705-31AE38F6-2B85-47FF-B91A-CD7307B27D86Q40220988-057B4811-6CA6-445D-BAA8-5C7417052E6CQ40235609-8E4915AA-E557-4D44-B258-BC94EBFB586DQ40339467-62FE3E60-C3EA-40F1-B3A2-01F2713430A0Q42280143-9A1108C2-3DE0-4086-ACE0-0F2FEB88453FQ44569389-5133853B-E0DA-45AE-A931-D48509459B6AQ47252143-81B98E47-134D-4ABD-B940-126690821CC5Q50533334-E410D7AE-1E14-4E7A-B8B6-F529023F91A9Q51784219-D1A0E380-A593-446A-9272-CBEC35D2C090Q56556724-28C92610-6234-4206-B169-D6B74698B81E
P2860
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@ast
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en-gb
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@nl
type
label
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@ast
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en-gb
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@nl
altLabel
A Candidate HIV/AIDS Vaccine ( ...... IV-1-Specific T-Cell Responses
@en
prefLabel
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@ast
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en-gb
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@nl
P2093
P2860
P50
P3181
P1433
P1476
A candidate HIV/AIDS vaccine ( ...... IV-1-specific T-cell responses
@en
P2093
José Luis Nájera
Juan García-Arriaza
Nolawit Tewabe
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0024244
P407
P577
2011-01-01T00:00:00Z